Pressmeddelanden

(Stockholm, Sweden, 12 January 2023) Post your questions to ISAB CEO Manoush Masarrat and Chairman Daniel Spasic for their joint Redeye event on March 6[th], 2023. The pair will take investor’s questions on 2022’s development and milestones, and how ISAB will keep growing momentum in 2023. Please submit your questions by February 27[th], 2023.

Inhalation Sciences AB (ISAB) has signed a new R&D contract worth 257,000 SEK (23,200 Euros) for Inhalation Research Services (IRS) work for a returning, long-standing customer – a major branded generic pharma company.  

Inhalation Sciences AB (ISAB) has received an order worth 1.9 MSEK (178,000 Euros) for an Inhalation Research Service (IRS) project with a mid-sized US pharma company. The project will use ISAB’s leading in vitro dissolution and absorption module DissolvIt[®][ ]to test the dissolution profiles of a new inhaled drug.

At this year’s DDL in Edinburgh, Scotland (7-9 December) Inhalation Sciences AB (ISAB) presented, for the first time, data from its clinical study of PreciseInhale, showing how the system out-performed commercial inhalers in targeting aerosols to specified regions of the lung. A second poster on ISAB’s in vitro simulation module DissolvIt was also presented. This was the first onsite DDL event since the end of European Covid-19 restrictions.

(Stockholm, Sverige, 22 november 2022) Inhalation Sciences AB meddelar att bolagets delårsrapport för tredje kvartalet 2022 nu finns tillgänglig på bolagets hemsida. För att läsa hela rapporten vänligen besök: http://inhalation.se/investors/finansiella-rapporter/

(Stockholm, Sweden, 22 November 2022) Inhalation Sciences AB announces that its interim report for the third quarter 2022 is now available on the company’s website. To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/

(Stockholm, 14 November 2022) In September 2022 Inhalation Sciences Sweden AB (ISAB) was awarded an FDA BAA (Broad Agency Announcement) contract for a research project evaluating the discriminative power of its DissolvIt[® ]in vitro dissolution technology. The project has now had its Kick-off meeting and is underway. ISAB has communicated previously on this project, most recently on 15 September 2022.

Inhalation Sciences has signed a new contract worth 1.17 million SEK (107,600 Euros) for an Inhalation Research Service (IRS) project aiming to establish differences in the dissolution profiles between a generic inhaled therapy and its reference drug – a key component of bioequivalence.  

(Stockholm 18 October 2022) Inhalation Research Services (IRS) has received a revised order increasing the amount that it will be paid by a US pharma company. The original order, communicated on 18 July 2022, was for 136,000 Euro. This has now been raised to 151,000 Euro as additional steps within the research project have been contracted out to IRS by the client.

Inhalation Research Services (IRS) has signed a new contract worth 806,000 SEK with a returning customer for a new in vivo study. ISAB CEO Manoush Masarrat: “Our IRS team and technology deliver world-class precision, performance and partnership – we’re pleased to welcome back this highly-valued client.”

With over 30 years in the life science and pharma industries and deep roots in respiratory, Inhalation Sciences' new Board member Jan Hellqvist has extensive experience growing SMEs to produce strong profit and growth. What are the key opportunities he sees for ISAB?

(Stockholm 20 September 2022) ISAB’s conference paper on its study validating PreciseInhale[®] for clinical use has been accepted by the Drug Delivery to the Lungs (DDL) conference 2022 - one of the inhalation markets’ most influential events. The study demonstrates that PreciseInhale[®] outperformed standard commercial inhalers and improved ‘regional targeting’ of aerosols to specific areas of the lungs. The data will be presented as a Poster at the event.

(Stockholm, 16 September 2022) Inhalation Sciences AB (ISAB) has received a new order from prestigious returning client the Department of Pharmaceutical Technology and Biopharmaceutics at the University of Vienna for the advanced in vitro cell exposure module XposeALI[®].

ISAB’s contract research organization Inhalation Research Services (IRS), has signed a new contract worth 1.39 million SEK (130K Euros) with a US respiratory pharmaceutical company. The new client has chosen ISAB’s unique in vitro lung simulation tool DissolvIt[®] for its project.

(Stockholm, 15 September 2022) Inhalation Sciences Sweden AB has been granted a BAA contract for dissolution research purposes. The project objective is to evaluate the discriminative power of the ISAB equipment DissolvIt[® ]by comparing drug formulations, aimed for administration via inhalation, with small differences. The project scope also includes in vitro in vivo correlation (IVIVC). The proposed work was approved by the FDA Center for Drug Evaluation and Research (CDER), not the NCTR, as previously stated.

Inhalation Sciences Sweden AB (publ) (”Bolaget”) avhöll den 5 september 2022 extra bolagsstämma. Stämman hölls med stöd av tillfälliga lagregler endast genom poströstning. Vid stämman fattades bland annat följande beslut.

(Stockholm, 5 September 2022) Inhalation Sciences AB (ISAB) has received a purchase order worth 360,000 SEK for development and required software update work from a long-term client, a leading global pharmaceutical company.

(Stockholm, Sweden, 29 August 2022) Inhalation Sciences AB announces that its interim report for the second quarter 2022, January 1 – June 30, is now available on the company’s website. To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/

(Stockholm, Sverige, 29 augusti 2022) Inhalation Sciences AB meddelar att bolagets delårsrapport för andra kvartalet 2022 nu finns tillgänglig på bolagets hemsida. För att läsa hela rapporten vänligen besök: http://inhalation.se/investors/finansiella-rapporter/

Aktieägarna i Inhalation Sciences Sweden AB (publ), org.nr 556665-6038, kallas härmed till extra bolagsstämma den 5 september 2022.

Inhalation Sciences Sweden AB:s (publ) (”Inhalation Sciences” eller “Bolaget”) styrelseledamot Klaus Gottwald har idag meddelat sin avsikt att lämna Bolagets styrelse. Valberedningen föreslår att Jan Hellqvist väljs som ny ledamot.

Inhalation Sciences Sweden AB’s (publ) (“Inhalation Sciences” or the “Company”) Board member Klaus Gottwald has today announced his intention to leave the Company’s Board of Directors. The Nomination Committee proposes that Jan Hellqvist be elected as new Board member.

(Stockholm, 4 August 2022) The US FDA (Food and Drug Administration) has approved Inhalation Sciences’ proposal for a research study aiming to validate the company’s in vitro lung simulation model DissolvIt[®] as an FDA-recommended dissolution technology, and ultimately a new ‘golden standard’ for dissolution testing for inhaled drugs. The FDA will support and co-finance the study with up to 250 000 USD annually for up to two years. The study will commence in the coming months.

(Stockholm 19 July 2022) ISAB has submitted an abstract to present data from its study validating PreciseInhale for clinical use, at the Drug Delivery to the Lungs (DDL) conference 2022 in Edinburgh, Scotland. The data demonstrate that PreciseInhale[®] outperformed standard commercial inhalers and improved ‘regional targeting’ of aerosols to specific areas of the lungs. DDL is one of the inhalation markets’ most influential events, with all major companies within the industry set to be present onsite, for the first time post-pandemic.  

(Stockholm 18 July 2022) A US company with an extensive pipeline in medical dermatology has chosen Inhalation Research Services (IRS), ISAB’s contract research organization, for a research project worth 1.45 million SEK (1.36 K Euro) into a new repurposed drug that is being reformulated for administration via the lungs. ISAB’s world-class expertise in inhalation, and its high-precision IPL (Isolated Perfused Lung) solution, were decisive in the client’s choice.

(Stockholm 29 June 2022) A new paper in the Journal of Environmental Science and Pollution Research explores the effects of inhaling, vs ingesting, PFOA (perfluoro-octanic acid), in house dust. PFOA is a common toxicant found in industries and households worldwide. In the study, carried out at the Institute of Environmental Medicine at Karolinska Institute, PreciseInhale achieved a standard deviation of 10-15% and demonstrated that PFOA concentration was four times higher via inhalation than ingestion – a novel result not previously published.

(Stockholm 23 June 2022) Inhalation Research Services (IRS), ISAB’s contract research organization, has signed a contract worth 581,000 SEK with a returning customer following a previous successful research project in February 2022. 

(Stockholm, Sverige, 12 juni 2022) Den 3 juni 2022 avslutades utnyttjandeperioden för teckningsoptioner av serie TO 1 för teckning av aktier i Inhalation Sciences Sweden AB (publ) (“Bolaget”). Inga teckningsoptioner utnyttjades.

On 3 June 2022, the period for exercising warrants of series TO 1 for subscription of shares in Inhalation Sciences Sweden AB (publ) (“the Company”) ended. No warrants were exercised.

(Stockholm, 9 June 2022) Inhalation Sciences (ISAB) and RISE Research Institutes of Sweden have collaborated successfully on a first proposal to a major global project into antibiotic resistance and inhaled antibiotics. RISE is an ISAB customer and a leading player within Sweden promoting collaborative research between academia, industry and the public sector.

(Stockholm, Sweden, 24 May 2022) Inhalation Sciences AB has received a credit line from a consortium of lenders of up to SEK 10 million, giving the company increased scope to finance its operations and growth over the next 12-14 months.

(Stockholm, Sverige, 24 maj 2022) Inhalation Sciences AB har erhållit en kreditram från ett konsortium av långivare om upp till 10 MSEK vilket skapar utrymme att finansiera bolagets verksamhet och tillväxt under de kommande 12-14 månaderna.

(Stockholm, Sweden, 24 May 2022) On 24 May Inhalation Sciences AB presented a major strategy update on its plans and goals for growth at RedEye in Stockholm Sweden. Watch the presentation here (https://www.redeye.se/video/event-presentation/843247/inhalation-sciences-strategy-update-by-manoush-masarrat-ceo-may-24-2022).

(Stockholm, Sverige, 24 maj 2022) Inhalation Sciences AB har erhållit en kreditram från ett konsortium av långivare om upp till 10 MSEK vilket skapar utrymme att finansiera bolagets verksamhet och tillväxt under de kommande 12-14 månaderna.

(Stockholm, Sweden, 24 May 2022) Inhalation Sciences AB has received a credit line from a consortium of lenders of up to SEK 10 million, giving the company increased scope to finance its operations and growth over the next 12-14 months.

Teckningskursen i Inhalation Sciences optionsserie TO 1 har, i enlighet med gällande optionsvillkor, fastställts till 10,00 SEK per aktie. Anmälningsperioden inleds den 23 maj 2022 och pågår till och med den 3 juni 2022. Innehavaren av teckningsoptioner äger rätt att för varje teckningsoption teckna en ny aktie i Inhalation Science till en teckningskurs om 10,00 SEK per aktie.

The subscription price in Inhalation Sciences' warrant of series TO 1 has, in accordance with the applicable terms for the warrants, been set at SEK 10.00 per share. The subscription period begins on May 23, 2022 and runs until June 3, 2022. The holder warrants have the right to subscribe for one new share in Inhalation Science for each warrant at a subscription price of SEK 10.00 per share.

(Stockholm, Sverige, 23 maj 2022) Inhalation Sciences AB meddelar att bolagets delårsrapport för första kvartalet 2022 nu finns tillgänglig på bolagets hemsida. För att läsa hela rapporten vänligen besök: http://inhalation.se/investors/finansiella-rapporter/

(Stockholm, Sweden, 23 May 2022) Inhalation Sciences AB announces that its first quarter interim report for January 1 – March 31, 2022 is now available on the company’s website. To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/

Inhalation Sciences Sweden AB (publ) (”Bolaget”) avhöll den 6 maj 2022 årsstämma. Årsstämman hölls med stöd av tillfälliga lagregler endast genom poströstning. Vid stämman fattades bland annat följande beslut.

(Stockholm, 5 May 2022) Inhalation Sciences (ISAB) has received positive feedback from the US FDA (Food and Drug Administration) on its white paper, previously communicated on 17 January 2022, that aims to validate the company’s DissolvIt[®] model as an FDA-recommended technology. ISAB has now been invited to submit a full proposal for its research project into DissolvIt[®]. If successful, the FDA will co-fund the project to the value of 250 KUSD (approx. 2.2 MSEK) annually for up to two years.

(Stockholm, Sverige, 12 April 2022) Inhalation Sciences AB has signed a new distribution with Quantaflux Industrial Co. Ltd that will cover the crucial China, Hong Kong and Macau markets. CEO Manoush Masarrat: “China is an important market for inhaled medicine, with robust R&D and a high level of local investment. We are delighted to be partnering With Quantaflux Industrial.”

(Stockholm, Sverige, 11 April 2022) Inhalation Sciences AB has signed a new distribution agreement with Omicron Research Ltd, a leading supplier of dissolution instruments in the UK and Ireland. CEO Manoush Masarrat: “The UK is a key market with enormous potential. We welcome this new agreement.”

(Stockholm, Sverige, 11 april 2022) Inhalation Sciences AB meddelar att bolagets årsredosvisning för 2021 nu finns tillgänglig på bolagets hemsida. För att läsa hela rapporten vänligen besök http://inhalation.se/investors/finansiella-rapporter/

(Stockholm, Sverige, 11 April 2022) Inhalation Sciences AB announces that its Annual Report 2021 is now available on the company’s website. To read the whole Report (in Swedish), please visit: http://inhalation.se/investors/finansiella-rapporter/

A leading nanotechnology company has returned to carry out another research project with Inhalation Research Services (IRS), ISAB’s contract research organization. The previous project, worth 584,000 SEK, began in February 2022. The new project, worth 491,000 SEK, will test slightly different versions of the company’s porous inhalable nanoparticles. Further studies with the same client are planned for later in 2022.

Aktieägarna i Inhalation Sciences Sweden AB (publ), org.nr 556665-6038, kallas härmed till årsstämma den 6 maj 2022.

(Stockholm, 18 March 2022) Inhalation Research Services (IRS) has signed a contract worth 74 000 Euros for a research project with a leading developer of inhaled generics. The project will compare in vitro data from ISAB’s dissolution module DissolvIt® with in vivo data from healthy volunteers, producing more milestone evidence of DissolvIt’s ability to produce predictive IVIVC (In Vitro-In Vivo Correlated) data. In January 2022 ISAB submitted a White Paper to the FDA aiming to validate DissolvIt® to become a recommended dissolution method for inhaled drug tests.

(Stockholm, 4 March 2022) Inhalation Sciences (ISAB) has received a new order worth 23 500 Euro from a returning customer – RISE, the Research Institute of Sweden, one of the country’s leading research bodies. RISE is purchasing ISAB’s Nebulizer Aerosol Generator, which enables precise dry powder-like aerosol to be generated from liquid solutions when mounted onto PreciseInhale®. RISE carries out a wide range of international research projects and collaborations, many funded by national and European public bodies.

(Stockholm, Sverige, 28 februari 2022) Inhalation Sciences AB meddelar att bolagets bokslutskommuniké 1 januari – 31 december 2021 nu finns tillgänglig på bolagets hemsida.